Numerous studies indicate that GLP-1 RAs may significantly reduce weight, liver injury, and liver fat content (163, 164), and can slow the progression of fibrosis in patients with NASH (156, 165, 166). This evidence concerns the gene GCG and metabolic dysfunction-associated steatohepatitis.